GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (NAS:GENE) » Definitions » Float Percentage Of Total Shares Outstanding

GENE (Genetic Technologies) Float Percentage Of Total Shares Outstanding : 95.79% (As of Dec. 14, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Genetic Technologies Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Genetic Technologies's float shares is 4.65 Mil. Genetic Technologies's total shares outstanding is 4.85 Mil. Genetic Technologies's float percentage of total shares outstanding is 95.79%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Genetic Technologies's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Genetic Technologies's Institutional Ownership is 1.86%.

Genetic Technologies Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Genetic Technologies's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=4.65/4.85
=95.79%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Technologies Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (NAS:GENE) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
ASX:IBX ASX:LDX TMO DHR XSWX:LONN A IQV IDXX MTD ILMN WAT NTRA LH SHSE:603259 DGX ICLR RVTY XPAR:BIM MEDP CRL
Traded in Other Exchanges
0A4N:UK DU8:Germany GTG:Australia
Address
60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Website
https://www.gtglabs.com
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.